Sigyn Therapeutics (SIGY) Total Current Liabilities (2016 - 2025)

Sigyn Therapeutics has disclosed Total Current Liabilities across 10 years of filings, most recently posting $4.0 million for Q3 2025.

• In Q3 2025, Total Current Liabilities fell 6.68% year-over-year to $4.0 million; the TTM figure through Sep 2025 stood at $4.0 million (down 6.68% YoY), while the FY2024 annual figure was $4.6 million, up 27.91% from the prior year.
• Total Current Liabilities came in at $4.0 million for Q3 2025 at Sigyn Therapeutics, down from $5.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $5.5 million in Q2 2025 to a low of $689213.0 in Q1 2021.
• Average Total Current Liabilities over 5 years is $2.9 million, with a median of $3.2 million recorded in 2023.
• Year-over-year, Total Current Liabilities plunged 78.48% in 2021 and jumped 197.99% in 2023.
• Over 5 years, Total Current Liabilities stood at $734218.0 in 2021, then surged by 179.03% to $2.0 million in 2022, then surged by 76.11% to $3.6 million in 2023, then advanced by 27.91% to $4.6 million in 2024, then fell by 13.55% to $4.0 million in 2025.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $4.0 million in Q3 2025, $5.5 million in Q2 2025, and $5.2 million in Q1 2025.